JJP Biologics reports positive interim phase 1b data for nebaprubart
Early clinical activity supports expansion into broader IgA‑mediated conditions
Read More
Author: John Pinching
Immunotherapy boost can spare more bladder cancer patients major surgery
Adding durvalumab to chemoradiation helps people avoid having their bladder removed
Read More
Deep Science Ventures and MDC partner to accelerate brain treatments
New collaboration aims to break barriers in brain‑targeted drug discovery
Read More
Aragen to manufacture Renaissance Pharma’s FDA Fast Track mAb
Aragen scales Daretabart to commercial-ready production following rapid 9‑month tech transfer
Read More
Spectrum of truth
Accuracy is a vital metric when confirming a spectrophotometer’s suitability
Read More- NICE backs daratumumab quadruplet for newly diagnosed transplant‑ineligible myeloma
- Anocca doses first patients with precision TCR‑T therapy
- Connecta launches phase 2a trial of neuroplasticity modulator
- Aquipta recommended by NICE for acute migraine treatment
- Talvey accepted for use in Scotland for relapsed and refractory multiple myeloma
